NASDAQ:VTGN - VistaGen Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.67
  • Forecasted Upside: 166.04 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.13
▼ -0.07 (-3.18%)
1 month | 3 months | 12 months
Get New VistaGen Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VTGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VTGN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.67
▲ +166.04% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for VistaGen Therapeutics in the last 3 months. The average price target is $5.67, with a high forecast of $6.00 and a low forecast of $5.00. The average price target represents a 166.04% upside from the last price of $2.13.
Buy
The current consensus among 4 investment analysts is to buy stock in VistaGen Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2021Jefferies Financial GroupInitiated CoverageBuy$6.00Low
i
2/18/2021Jefferies Financial GroupInitiated CoverageBuy$6.00High
i
1/4/2021William BlairUpgradeMarket Perform ➝ OutperformN/A
i
Rating by T. Lugo at William Blair
12/22/2020Maxim GroupBoost Price Target$3.00 ➝ $5.00Low
i
Rating by Jason McCarthy at Maxim Group
10/8/2020AegisInitiated CoverageBuy$6.00Low
i
8/11/2020Maxim GroupReiterated RatingBuy$3.00High
i
Rating by Jason McCarthy at Maxim Group
6/26/2020Maxim GroupReiterated RatingBuy$1.00Medium
i
Rating by Jason McCarthy at Maxim Group
5/29/2020Maxim GroupInitiated CoverageBuy$1.00High
i
Rating by Jason McCarthy at Maxim Group
4/29/2020Maxim GroupInitiated CoverageBuy$1.00Low
i
Rating by Jason McCarthy at Maxim Group
12/2/2019Chardan CapitalReiterated RatingNeutralHigh
i
Rating by G. Amusa at Chardan Capital
11/14/2019William BlairDowngradeOutperform ➝ Market PerformHigh
i
Rating by Tim Lugo at William Blair
11/3/2019Chardan CapitalReiterated RatingHold$0.70Low
i
Rating by J. Schmerler at Chardan Capital
10/15/2019Maxim GroupSet Price TargetBuy$4.00N/A
i
Rating by Jason McCarthy at Maxim Group
10/9/2019William BlairReiterated RatingBuyN/A
i
Rating by Tim Lugo at William Blair
10/8/2019Maxim GroupSet Price TargetBuy$4.00Low
i
Rating by Jason McCarthy at Maxim Group
8/28/2019William BlairInitiated CoverageOutperformHigh
i
Rating by T. Lugo at William Blair
7/29/2019Chardan CapitalReiterated RatingNeutralHigh
i
Rating by J. Schmerler at Chardan Capital
7/22/2019Chardan CapitalDowngradeBuy ➝ Neutral$22.00 ➝ $0.70High
i
5/2/2019Maxim GroupSet Price TargetBuy$6.00High
i
Rating by Jason McCarthy at Maxim Group
3/6/2019Maxim GroupReiterated RatingBuy$6.00High
i
Rating by Caroline Palomeque at Maxim Group
11/4/2018OppenheimerSet Price TargetBuy$6.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/25/2018Maxim GroupSet Price TargetBuy$6.00Low
i
Rating by Caroline Palomeque at Maxim Group
10/3/2018Maxim GroupSet Price TargetBuy$6.00High
i
Rating by Caroline Palomeque at Maxim Group
9/13/2018Maxim GroupSet Price TargetBuy$6.00Medium
i
Rating by Caroline Palomeque at Maxim Group
9/5/2018Maxim GroupSet Price TargetBuy$6.00Low
i
Rating by Caroline Palomeque at Maxim Group
9/4/2018OppenheimerSet Price TargetBuy$6.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/30/2018Maxim GroupSet Price TargetBuy$6.00High
i
Rating by Caroline Palomeque at Maxim Group
8/24/2018OppenheimerSet Price TargetBuy$6.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/14/2018Maxim GroupSet Price TargetBuy$6.00High
i
Rating by Caroline Palomeque at Maxim Group
8/6/2018Maxim GroupSet Price TargetBuy$6.00Low
i
Rating by Caroline Palomeque at Maxim Group
6/29/2018Chardan CapitalReiterated RatingBuy$22.00Medium
i
6/27/2018Maxim GroupInitiated CoverageBuy$6.00Low
i
5/24/2018OppenheimerInitiated CoverageBuy$6.00High
i
5/24/2018UBS GroupInitiated CoverageOutperform$6.00High
i
2/8/2018Chardan CapitalLower Price TargetBuy ➝ Buy$30.00 ➝ $22.00Medium
i
4/27/2017Maxim GroupReiterated RatingBuy$4.00Medium
i
Rating by Lauren Chung at Maxim Group
3/28/2017Maxim GroupInitiated CoverageBuy ➝ Buy$4.00Low
i
7/7/2016WallachBeth CapitalInitiated CoverageBuy$17.00N/A
i
5/23/2016Chardan CapitalReiterated RatingBuyN/A
i
Rating by G. Amusa at Chardan Capital
(Data available from 3/6/2016 forward)
VistaGen Therapeutics logo
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $2.13
$1.96
$2.24

50 Day Range

MA: $2.25
$1.89
$2.96

52 Week Range

Now: $2.13
$0.30
$3.18

Volume

2,915,685 shs

Average Volume

4,625,232 shs

Market Capitalization

$301.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of VistaGen Therapeutics?

The following sell-side analysts have issued research reports on VistaGen Therapeutics in the last twelve months: Aegis, Jefferies Financial Group Inc., Maxim Group, William Blair, and Zacks Investment Research.
View the latest analyst ratings for VTGN.

What is the current price target for VistaGen Therapeutics?

3 Wall Street analysts have set twelve-month price targets for VistaGen Therapeutics in the last year. Their average twelve-month price target is $5.67, suggesting a possible upside of 166.0%. Jefferies Financial Group Inc. has the highest price target set, predicting VTGN will reach $6.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $5.00 for VistaGen Therapeutics in the next year.
View the latest price targets for VTGN.

What is the current consensus analyst rating for VistaGen Therapeutics?

VistaGen Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VTGN will outperform the market and that investors should add to their positions of VistaGen Therapeutics.
View the latest ratings for VTGN.

What other companies compete with VistaGen Therapeutics?

How do I contact VistaGen Therapeutics' investor relations team?

VistaGen Therapeutics' physical mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-577-3600 and its investor relations email address is [email protected] The official website for VistaGen Therapeutics is www.vistagen.com.